Value of18Fluorodeoxyglucose–Positron-Emission Tomography in Amyotrophic Lateral Sclerosis | Zendy

Koen Van Laere | Zendy; Annelies Vanhee | Zendy; Jolien Verschueren | Zendy; Liesbeth De Coster | Zendy; An Driesen | Zendy; Patrick Dupont | Zendy; Wim Robberecht | Zendy; Philip Van Damme | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Value of¹⁸Fluorodeoxyglucose–Positron-Emission Tomography in Amyotrophic Lateral Sclerosis

Author(s) -

Koen Van Laere,

Annelies Vanhee,

Jolien Verschueren,

Liesbeth De Coster,

An Driesen,

Patrick Dupont,

Wim Robberecht,

Philip Van Damme

Publication year - 2014

Publication title -

jama neurology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.298

H-Index - 231

eISSN - 2168-6157

pISSN - 2168-6149

DOI - 10.1001/jamaneurol.2014.62

Subject(s) - c9orf72 , amyotrophic lateral sclerosis , positron emission tomography , population , medicine , nuclear medicine , pathology , frontotemporal dementia , dementia , disease , environmental health

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder primarily affecting the motor system, with extramotor involvement to a variable extent. Biomarkers for early differential diagnosis and prognosis are needed. An autosomal dominant hexanucleotide (GGGGCC) expansion in the noncoding region of the chromosome 9 open reading frame 72 (C9orf72) gene is the most frequent genetic cause of ALS, but its metabolic pattern has not been studied systematically.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research